Kringle Pharma, Inc.
4884.T · JPX
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.26 | 0.28 | -0.04 | 1.14 |
| FCF Yield | 0.00% | -12.20% | -16.02% | 0.72% |
| EV / EBITDA | -1.69 | -3.80 | -2.44 | 1.34 |
| Quality | ||||
| ROIC | -46.16% | -31.11% | -36.88% | -13.99% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 77.44% |
| Cash Conversion Ratio | 0.82 | 0.87 | 0.81 | -0.05 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.41% | -41.11% | -37.94% | -5.72% |
| Free Cash Flow Growth | 100.00% | 4.05% | -4,462.47% | 102.82% |
| Safety | ||||
| Net Debt / EBITDA | 1.77 | 2.83 | 2.40 | 6.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.25 |
| Cash Conversion Cycle | 306.83 | 261.07 | 431.41 | 1,507.70 |